ArticleLeukemia2020
Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review.Blood cancer journal · 2023Pooled it
- Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.European journal of haematology · 2025Trial
- More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected].Blood advances · 2023Trial
- Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.Blood cancer journal · 2022Trial
- AI-derived whole-body MRI metrics in patients with multiple myeloma reveal unique insights into body composition and outcomes.Blood advances · 2026Observational
- Article
- Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy.Blood advances · 2026Review
- Cognitive speed-accuracy dissociation in multiple myeloma: a cross‑sectional study.BMC neuroscience · 2026Article
- Prediagnostic opioid use and survival in multiple myeloma: a nationwide register-based study.Scientific reports · 2026Article
- Advances in the application of frailty scoring in the diagnosis and management of elderly patients with multiple myeloma (Review).Oncology reports · 2026Review
- Development and multinational validation of a multiple myeloma-specific comorbidity index using real-world cohorts: CAREMM-2108.Blood cancer journal · 2026Article
- Perspective recommendations on geriatric support for older adults with multiple myeloma based on challenges faced by a multidisciplinary team.Frontiers in oncology · 2026Article
- Combining IMWG GA and hematopoietic score to optimize the evaluation of dynamic chemotherapy tolerance in multiple myeloma.Annals of medicine · 2025Article
- Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.Blood advances · 2025Article
- EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.Nature reviews. Clinical oncology · 2025Review
- Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer.HemaSphere · 2025Article
- A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma.Blood cancer journal · 2025Article
- Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan.International journal of hematology · 2025Article
- Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia.Skeletal radiology · 2025Article
- Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region.Clinical hematology international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the treatment landscape continues to evolve towards the application of precision medicine in multiple myeloma (MM), there is a clear need to identify those patients who are at risk of not achieving the maximum benefit whilst exposed to the highest level of toxicity. This group of patients, defined as frail, is an unmet clinical need. However, how we define such a vulnerable group of patients with MM remains to be clarified. An integral aspect of this is to define the physiological age and capacity of patients with MM to deal with the burden of their disease and it's treatment. Such assessments may include not only functional and clinical assessments but also laboratory-based biomarkers of frailty, aging and senescent cellular burden. A need to develop, test and validate clinical screening scores before their adoption into clinical practice is mandated. This position paper from the European Myeloma Network aims to review what is known about defining frailty in MM, and how we can advance this knowledge for the design of clinical trials and ultimately how we deliver treatment in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.